- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Affinia Therapeutics Receives Approval for UPBEAT Trial
The Phase 1/2 clinical trial will evaluate a novel gene therapy for a rare genetic disorder.
Apr. 6, 2026 at 1:17pm
Got story updates? Submit your updates here. ›
Affinia Therapeutics' investigational gene therapy aims to address the underlying genetic cause of a rare disorder.Waltham TodayAffinia Therapeutics, a biotechnology company focused on developing gene therapies, has received approval from Health Canada to initiate the UPBEAT clinical trial, a Phase 1/2 study evaluating a novel gene therapy for a rare genetic disorder.
Why it matters
The UPBEAT trial represents an important milestone for Affinia Therapeutics as it advances its pipeline of investigational gene therapies. Successful completion of this trial could pave the way for a potential new treatment option for patients living with this rare and debilitating condition.
The details
The UPBEAT trial will assess the safety, tolerability, and preliminary efficacy of Affinia's investigational gene therapy in patients with the rare genetic disorder. The study will enroll participants at multiple clinical sites across Canada.
- Affinia Therapeutics received approval from Health Canada on April 6, 2026 to initiate the UPBEAT trial.
The players
Affinia Therapeutics
A biotechnology company focused on developing gene therapies for rare genetic disorders.
What’s next
Affinia Therapeutics plans to begin enrolling patients in the UPBEAT trial in the coming months, with initial data expected in late 2027.
The takeaway
The approval of the UPBEAT trial represents an important step forward in Affinia Therapeutics' efforts to develop a potential new treatment option for patients living with this rare genetic disorder.
